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Abstract
Background: Elevated glucose-regulated protein 78 (GRP78) levels in tissues have been known to be related with poor
prognosis in hepatocellular carcinoma (HCC) patients. Though the variants in the 39 untranslated region (UTR) of GRP78
gene were not associated with HCC risk, we wonder whether these polymorphisms affect survival of HCC patients.
Methodology/Principal Findings: Blood samples of HCC patients were maintained in our specimen bank between 1996 to
2003. DNA from 576 unrelated and resectable patients with HCC was typed for rs16927997 (T.C), rs1140763 (T.C) and
rs12009 (T.C) by TaqMan assays. The Kaplan-Meier method and log-rank test were used to estimate overall survival.
Linkage disequilibrium (LD) analysis identified a total of 3 haplotypes and 6 diplotypes in this region. The distribution of
haplotype was not related to the clinical characteristics. Univariate analysis showed that the allele, genotype, haplotype and
diplotype did not effect the survival. None of the clinical features show a significant association (Pcorreced.0.05) with overall
patient outcome in multiple comparisons.
Conclusions/Significance: There is no noteworthy influence of 39 UTR variants in the GRP78 on prognosis of resectable HCC
in the Chinese population.
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Introduction
Incidence is increasing and hepatocellular carcinoma (HCC)
has risen to become the 5th commonest malignancy worldwide
and the third leading cause of cancer-related death, exceeded only
by cancers of the lung and stomach. Every year approximately
0.5–1 million new cases of HCC are diagnosed, causing 600
thousand deaths globally per year [1,2]. China has one of the
highest prevalent areas of HCC, mainly because of chronic
hepatitis B carriers accounting for more than 10% of its
population. However, only about 1/5 of hepatitis B virus (HBV)
carriers are expected to develop HCC in their lifetime [3].
Therefore, host genetic factor may play important roles in
hepatocarcinogenesis.
Glucose-regulated protein 78 (GRP78, 78 kDa), also called
heat shock 70 kDa protein 5 (HSPA5), is a major endoplasmic
reticulum (ER) chaperone and HSP70 family member that
functions to bind and chaperone secretory proteins and
promote dis-aggregation and proper protein folding and
assembly [4,5]. GRP78 is involved in the progression of
HCC, and elevated GRP78 levels in tissues have been known
to be related with poor prognosis [6]. Though GRP78, including
single-nucleotide polymorphisms (SNPs) in its 39 untranslated
region (UTR), were not associated with HBV infection, our
previous study also showed that a common SNP (rs430397 G.A)
in the intron 5 of GRP78 gene was associated with risk and
prognosis of primary HCC [7,8]. Especially, our recent study
showed that the haplotypic block in its 39 UTR (including
rs16927997, rs1140763 and rs12009) were not associated
with HCC risk [9]. We wonder whether these 39 UTR variants
are the contributing factors to HCC prognosis. Therefore, we
investigated the associations of SNPs in the 39 UTR of GRP78
with overall survival among a Han Chinese population with
HCC.
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Patients
All participants provided written informed consents (from their
guardians where necessary). This study was conducted in
accordance with the tenets of the Declaration of Helsinki and its
amendments and approved by the ethics committee of Guangzhou
Medical College. The study population consisted of 576 HCC
cases who inhabited in Guangzhou City or its neighboring
townships at Guangdong province, a well-known high-risk region
for HCC located in southern China between 1996 to 2003, which
described previously [8]. The diagnosis of HCC was verified by
liver histology, or based on the findings of radiological features
suggestive of HCC in at least two image examinations including
abdominal ultrasound, contrast enhanced dynamic computed
tomography (CT), magnetic resonance imaging (MRI), and
hepatic angiography, or by a single positive imaging technique
associated with serum a-fetoprotein (AFP) level $25 mg/L. All
patients were shown not to have other cancers by an initial
screening examination.
Genotyping
Genomic DNA was extracted from peripheral blood leukocytes
using QIAGEN QIAamp DNA Mini Blood Kit (Hilden,
Germany). Three validated SNPs (rs16927997 T.C, rs1140763
T.C and rs12009 T.C) in the 39 UTR of GRP78 gene were
detected by the TaqMan Assay-by-Design service (Applied
Biosystems, Foster City, CA). The details of sequences and
reaction conditions are available upon request (https://products.
appliedbiosystems.com/ab/en/US/adirect/ab). PCR was per-
formed using the TaqMan Universal Master Mix without UNG
on the ABI PRISM 7900HT Sequence Detection System (Applied
Biosystems, Foster City, CA) and heated to 95uC for 10 minutes
followed by 40 cycles of 92uC for 15 seconds and 60uC for 1
minute, as described previously.
Follow-up
The patients were followed up for a range of 6,66 months.
Data were collected from at least one of the following sources: the
hospitals inpatient and outpatient records (staff periodically review
computerized hospital tumor registry data or medical records for
updated information), primary physician’s offices, and patient or
family contact. When it is observed that a patient has had no
recent visit, the general practitioner of the patient is contacted to
ascertain the patient’s vital status. The primary endpoint was
overall survival duration from the date of HCC diagnosis to the
date of death. Patients who were alive at the end of the study
period were censored on the last date of follow-up. The end of the
observation period is the end of April 2008. In the period of
analysis, 331 patients had died within 5 years of diagnosis, 35
patients were alive and 62 patients lost follow-up.
Statistical analysis
The distribution of genotype was tested for Hardy-Weinberg
equilibrium with the Pearson Chi-square test. Haplotypes were
constructed by Haploview version 3.2 [10]. The diplotypes were
constructed on the base of SNPs found in this study. Associations
between haplotype distribution and clinicopathological variables
were also assessed by the Chi-square test. The Kaplan-Meier
method was used to estimate overall survival by allele, genotype,
haplotype or diplotype and the log-rank test was used to compare
the survival distributions. The wild-type allele/genotype and the
corresponding haplotype/diplotype were taken as the references.
To account for multiple testing, the Bonferroni correction was
applied. All statistical evaluations were done using SPSS version
13.0 (SPSS Inc, Chicago, IL, USA). All tests were two-tailed, and P
or Pcorrected ,0.05 was considered statistically significant.
Results
Baseline characteristics for the three haplotype groups are
presented in Table 1. Among the 576 patients in this study, 344
(59.7%) are male, and 490 (85.1%) are cirrhosis. With tumor,
nodes, metastasis-classification (TNM) stage, 173 (30.0%) had
advanced stage (III/IV) and 403 (70.0%) of the patients had
primary stage (I/II). The genotype frequencies were in good
agreement with the expected genotype distributions and consistent
with Hardy-Weinberg equilibrium in cases (data not showed). By
grouping the three SNPs together, three haplotypes with frequency
larger than 1% were found in case population according linkage
disequilibrium (LD) pattern. LD analysis further revealed that all
selected SNPs were in strong LD with pairwise D’=1, and formed
a haplotype block according to the internally developed solid spine
of LD in our study population. The analyzed haplotype
distribution was as follows: 614 (53.3%) T-T-T, 461 (40.0%) T-
C-C, and 77 (6.7%) C-C-T. The distribution of haplotype was not
related to age, gender, HBsAg, AFP, tumor size, cirrhosis, or
TNM stage (P.0.05, respectively).
The overall 5-year survival rate of the 576 patients was 10.4%.
Univariate analysis of prognostic significance of the polymor-
phisms was performed for overall survival by the Kaplan-Meier
method. We did not find any overall survival difference between
the wildtype allele/genotype and mutant allele/genotype in
rs16927997, rs1140763 and rs12009 (Log-rank P.0.05, respec-
Table 1. Demographic characteristics and haplotypic
distributions of the 39 untranslated region (UTR) of GRP78
gene among cases with HCC.
Characteristics T-T-T T-C-C C-C-T p*
No. % No. % No. %
Age, years #40 83 13.5 55 11.9 8 10.4 0.872
.40, #60 309 50.3 230 49.9 39 50.6
.60 222 36.2 176 38.2 30 39.0
Sex Female 261 42.5 178 38.6 25 32.5 0.153
Male 353 57.5 283 61.4 52 67.5
HBV HBsAg (2) 175 28.5 113 24.5 18 23.4 0.276
HBsAg (+) 439 71.5 348 75.5 59 76.6
Serum AFP ,25 ng/ml 97 15.8 83 18.0 6 7.8 0.074
$25 ng/ml 517 84.2 378 82.0 71 92.2
Tumor size (cm) #5 135 22.0 111 24.1 20 26.0 0.874
.5, #10 340 55.4 248 53.8 42 54.5
.10 139 22.6 102 22.1 15 19.5
Cirrhosis No 102 16.6 64 13.9 6 7.8 0.088
Yes 512 83.4 397 86.1 71 92.2
TNM stage I 175 28.5 128 27.8 19 24.7 0.310
II 271 44.1 178 38.6 35 45.4
III 110 17.9 105 22.8 13 16.9
IV 58 9.4 50 10.8 10 13.0
*Chi-square test.
AFP, a-fetoprotein; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; TNM,
tumor, nodes, metastasis-classification.
doi:10.1371/journal.pone.0017783.t001
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and genotype levels, there were no significant differences in overall
survival comparing the other haplotypes or diplotypes with the
referred haplotype TTT or diplotype TCC/TTT (Log-rank
P.0.05, respectively, Fig. 1 G or H).
The patients were divided into two subgroups according to the
clinical characteristics or cutoff values of serum AFP. Survival
curves were compared between the two subgroups. Table 2 lists
the prognostic factors of the patients and shows the results of the
univariate survival analysis. HBV infection and cirrhosis were
found to be possible prognostic factors for patients with HCC
(Log-rank P=0.033 and 0.018, respectively). After Bonferroni
correction in multiple comparisons, none of the clinical features
showed a significant association (Pcorrected.0.05) with overall
patient outcome. However, HBV infection status and cirrhosis
showed the strongest association with survival.
Discussion
HCC is the most common primary epithelial malignancy
occurring in the liver. It is a malignant tumor that arises from
hepatocytes and is characterized by a trabecular, plate-like, or
sinusoidal growth patterns with vascular invasion. In microscopic
morphology, the tumor cells of HCC exhibit varying degrees of
hepatocellular differentiation [11,12]. Though remarkable im-
provements have been done in last decade on the understanding
the molecular mechanisms involved in liver oncogenesis, the
prognosis of patients affected by HCC is still poor for most of
them [13].
In this study, we demonstrated for the first time the prognostic
role of GRP78 39 UTR polymorphisms in patients with resectable
HCC. The attribution of variant haplotype was not related to
demographic characteristics. Univariate analysis showed that the
age, gender, tumor size, TNM stage, serum AFP, HBV, cirrhosis
and the 39 UTR polymorphisms (allele, genotype, haplotype and
diplotype) are not independent prognostic factors for HCC in this
population. Our hypothesis, based on the result displaying an
involvement of these genetic variants in the susceptibility to HCC,
was tested on a large cohort of prospectively followed-up patients
with a large number of events allowing us to be confident in such a
conclusion.
Large number of data showed that allele variants in certain
genes are diagnostic and/or prognostic markers for primary HCC
[14,15,16,17,18]. And the genetic difference of the gene related to
disease process or survival may help us to predict each individual’s
susceptibility of developing serious disease and/or predict
prognosis that can improve the cure rate substantially
[19,20,21]. Therefore, there is intense interest in gaining a better
understanding of the hepatocarcinogenesis to develop more
reliable biomarkers to predict poor outcome. However, the genetic
mechanisms for the progression of HCC remain largely unclear
and need to be further established.
GRP78 is a central regulator of endoplasmic reticulum
homeostasis due to its multiple functional roles, involving in
polypeptide translocation across the ER membranes and acts as an
apoptotic regulator by protecting the host cell against ER stress-
induced cell death [22,23]. Unfortunately, in many of the excellent
studies, the exact mechanism is not known. However, we believe it
is not a misleading statement that most of the cytoprotective effects
of GRP78 come from the inhibition of stress-induced apoptosis
[24].
As a hospital-based study, our patients with HCC were
represent an unconsecutive series and were randomly selected,
and the tumors all had been cured by surgical resect. And
therefore inherent selection bias cannot be completely excluded.
Overall however, our findings would suggest that there is no
Table 2. Univariate survival analyses of possible prognostic factors.
Subgroups N Univariate
5-years survival rate Log-rank PP corrected
Age #50 (years) 217 13.6%
.50 (years) 359 9.4% NS NS
Gender Females 232 12.0%
Males 344 9.1% NS NS
HBV infection HBsAg (2) 153 14.5%
HBsAg (+) 423 8.6% 0.033 NS
Serum AFP Low (,25 ng/ml) 93 13.4%
High ($25 ng/ml) 483 8.9% NS NS
Tumor size #5 (cm) 133 14.0%
.5 (cm) 443 9.0% NS NS
Cirrhosis No 86 15.2%
Yes 490 8.7% 0.018 NS
TNM stage I/II 403 13.6%
III/IV 173 8.4% NS NS
AFP, a-fetoprotein; HBV, hepatitis B virus; NS, not significant; TNM, tumor, nodes, metastasis-classification.
doi:10.1371/journal.pone.0017783.t002
Figure 1. Kaplan-Meier survival curves show that overall survivals of 576 cases with HCC were not associated with the different
alleles, genotypes, haplotypes and diplotypes in the GRP78 gene including rs16927997, rs1140763 and rs12009. P value was
calculated using a log-rank test. The wildtype alleles, homozygotes, and the corresponding haplotype and diplotype were designated as the referent.
doi:10.1371/journal.pone.0017783.g001
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PLoS ONE | www.plosone.org 4 March 2011 | Volume 6 | Issue 3 | e17783noteworthy influence of 39 UTR variants in the GRP78 on
prognosis of resectable HCC in the Chinese Han population,
despite the fact that the gene is considered an important
participant in promoting tumor proliferation, survival, metastasis,
and resistance to a wide variety of therapies. Our findings,
however, require further verification from a much larger sample
size with follow-up information on patient’s survival outcomes.
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